Anthropic Says Claude Found a New Enzyme System in Bacterial Viruses

Anthropic CEO Repeats Five-to-10-Year Disease-Cure Forecast After Claude Finding

Anthropic CEO Dario Amodei has renewed his forecast that AI could help cure most diseases within five to 10 years, pointing to a discovery made with Claude. The model found a distinctive pattern around an enzyme in genetic data, and Anthropic’s scientists began testing it. They still do not know what the system does, let alone whether it could help treat disease.

Amodei made the case Wednesday while discussing Anthropic’s newly disclosed research. His forecast is not a claim that Claude found a cure: he described curing most diseases in five to 10 years as a goal he had set out before, and said it would require AI to help at every stage of the biomedical pipeline. The reported discovery is an early test of a narrower idea—that AI can help scientists find biological systems worth investigating.

The enzyme itself was not new. Earlier researchers had identified it in a virus that infects bacteria. Anthropic says Claude spotted something that had escaped notice nearby: an associated gene and a long array of evenly spaced DNA repeats. The company calls the resulting system array-associated reverse transcriptases, or ART. A reverse transcriptase is an enzyme that copies RNA into DNA.

Scientists gave Claude a broad prompt to search DNA-sequence data for interesting reverse transcriptases. Anthropic says roughly 950 agents spent 21 hours on the search, gathering more than 200,000 enzymes and narrowing thousands of candidate systems for closer examination. One agent flagged the repeat pattern; further analysis led to a report for human review. That division of labor matters: Claude identified a candidate system, rather than independently proving its function.

Human scientists carried out the lab experiments, with Claude helping propose what to test. Their initial work found that ART’s repeat array produces distinct short RNA molecules. Anthropic sees a possible resemblance to CRISPR, a naturally occurring system that has been turned into a gene-editing tool. But resemblance is not the same as a working editing mechanism. Anthropic says experiments to determine ART’s primary function are still underway.

a goal that sounds impossible, but one I believe is just barely possible if AI is applied to every stage of the pipeline.

The early result has drawn both interest and restraint. Stanford bioengineering associate professor Stanley Qi told Al Jazeera that Claude’s pursuit of a hard-to-spot pattern was exciting; he said AI could help researchers explore complex biological systems faster. Microbiologist Kevin Blake warned against a much bigger leap. A CRISPR-like pattern in nature does not show that ART rivals CRISPR as a technology, he said, or that it can become a practical tool or therapy.

Amodei’s argument is that faster fundamental discoveries could give researchers more promising drug targets, therapies and tools to investigate. He does not expect AI to shorten clinical trials. Any treatment emerging from this work would still need standard testing and regulatory review. For ART, even those downstream questions are premature: its biological role and possible use remain unestablished.

Anthropic’s research setup also draws a present-day boundary around the word “autonomous.” Its scientists supplied the initial direction, reviewed Claude’s work and performed the physical experiments. Amodei has suggested Claude might someday control lab equipment with safeguards, but said Anthropic is not doing that today. The next test of this finding is less sweeping than the disease-cure forecast: establishing what ART actually does.